Sle
-
Upload
bhupendra-shah -
Category
Health & Medicine
-
view
25 -
download
0
Transcript of Sle
![Page 1: Sle](https://reader036.fdocuments.us/reader036/viewer/2022083103/5886d3c71a28ab776a8b4e6b/html5/thumbnails/1.jpg)
Systemic Lupus Erythematosus
![Page 2: Sle](https://reader036.fdocuments.us/reader036/viewer/2022083103/5886d3c71a28ab776a8b4e6b/html5/thumbnails/2.jpg)
Who can see the pain within my heart?
![Page 3: Sle](https://reader036.fdocuments.us/reader036/viewer/2022083103/5886d3c71a28ab776a8b4e6b/html5/thumbnails/3.jpg)
COMPARE……..
![Page 4: Sle](https://reader036.fdocuments.us/reader036/viewer/2022083103/5886d3c71a28ab776a8b4e6b/html5/thumbnails/4.jpg)
Epidemiology
![Page 5: Sle](https://reader036.fdocuments.us/reader036/viewer/2022083103/5886d3c71a28ab776a8b4e6b/html5/thumbnails/5.jpg)
Clinical feature
Manifestation Prevalence(%)
Fatigue/malaise/fever 95Cutaneous 80hematologic 85Neurologic 60Cardiopulmonary 60Renal 30Gastrointestinal 40
Thrombosis 15
![Page 6: Sle](https://reader036.fdocuments.us/reader036/viewer/2022083103/5886d3c71a28ab776a8b4e6b/html5/thumbnails/6.jpg)
Investigation:
Screening: ANA
Specific:Anti-ds DNA
Diasease activity;Complement, Anti ds DNA, active
sediment in urine
![Page 7: Sle](https://reader036.fdocuments.us/reader036/viewer/2022083103/5886d3c71a28ab776a8b4e6b/html5/thumbnails/7.jpg)
SlICC clinic criteria for SLEClinical manifestation Immunologic
manifestation Acute cutaneous Chronic cutaneous Oral ulcer Serositis Alopecia Synovitis Renal Neurologic Hemolytic anemia Leucopenia thromcytopenia
ANA Anti-ds DNA Anti-Sm Antiphospholipid Low serum
complement Positive DCT4 CRITERIA AT ALEAST 1
CRITERIA EACH FROM CLINICAL AND IMMUNOLOGICAL
BIOPSY PROVEN LUPUS NEPHRITIS+ANA/ANTI DS DNA
![Page 8: Sle](https://reader036.fdocuments.us/reader036/viewer/2022083103/5886d3c71a28ab776a8b4e6b/html5/thumbnails/8.jpg)
Treatment
Not life or organ
threatening
Life or organ threatening
High dose glucocorticoids
Addition of immunosuppressive
Mycophenolate/cyclophosphamide
![Page 9: Sle](https://reader036.fdocuments.us/reader036/viewer/2022083103/5886d3c71a28ab776a8b4e6b/html5/thumbnails/9.jpg)
What about ?
hydoxychlroquinine
![Page 10: Sle](https://reader036.fdocuments.us/reader036/viewer/2022083103/5886d3c71a28ab776a8b4e6b/html5/thumbnails/10.jpg)
Scleroderma
![Page 11: Sle](https://reader036.fdocuments.us/reader036/viewer/2022083103/5886d3c71a28ab776a8b4e6b/html5/thumbnails/11.jpg)
Definition
Connective tissue disorder, involve multisystem
Characterised by skin thickening
![Page 12: Sle](https://reader036.fdocuments.us/reader036/viewer/2022083103/5886d3c71a28ab776a8b4e6b/html5/thumbnails/12.jpg)
Epidemiology
Female predominant(4.6:1)
Peak age of onset: 30-50 years
![Page 13: Sle](https://reader036.fdocuments.us/reader036/viewer/2022083103/5886d3c71a28ab776a8b4e6b/html5/thumbnails/13.jpg)
Types of systemic sclerosisCharacterstics Limited
cutaneousDiffuse cutaneous
Skin involvement Limited distal to elbow
Diffusely involve
Raynauds phenomenon
Precedes the skin involvement
Coincident
ILD Mild Common and severe
Renal crisis Rare Common
Antibodies Anticentromere Ab Anti-topoisomerase Ab.
![Page 14: Sle](https://reader036.fdocuments.us/reader036/viewer/2022083103/5886d3c71a28ab776a8b4e6b/html5/thumbnails/14.jpg)
Clinical features
![Page 15: Sle](https://reader036.fdocuments.us/reader036/viewer/2022083103/5886d3c71a28ab776a8b4e6b/html5/thumbnails/15.jpg)
Raynaud phenomenon
![Page 16: Sle](https://reader036.fdocuments.us/reader036/viewer/2022083103/5886d3c71a28ab776a8b4e6b/html5/thumbnails/16.jpg)
INVESTIGATION
Diagnosis SupportiveACA: limited cutaneous
SSC
Anti-toposisomerase I: Diffuse cutaneous SS
Full thickness skin biopsy
ECHO:
PFT:
UGI endoscopy:
Nail cappillaroscopy:
![Page 17: Sle](https://reader036.fdocuments.us/reader036/viewer/2022083103/5886d3c71a28ab776a8b4e6b/html5/thumbnails/17.jpg)
Treatment
Definative supportive Disease modifying
therapy
Glucocorticoids:only if indicated
Cyclophosphamide:for ILD
Mehtotrexate/mycophenolate mofetil:little benefit
Antifibrotic therapy:D-penicillamine
Vascular therapy:Calcium channel blocker
gastrointestinal :
Pulmonary artery hypertension:
Renal crisis:
![Page 18: Sle](https://reader036.fdocuments.us/reader036/viewer/2022083103/5886d3c71a28ab776a8b4e6b/html5/thumbnails/18.jpg)
Treatment
No any treatment to significantly alter the course the natural history of disease.
![Page 19: Sle](https://reader036.fdocuments.us/reader036/viewer/2022083103/5886d3c71a28ab776a8b4e6b/html5/thumbnails/19.jpg)
Thank you